Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma

  • Inflammatory Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to describe the initial experience, efficacy, and safety of ripasudil hydrochloride hydrate (ripasudil), a Rho-associated kinase inhibitor eye drop, for uveitic glaucoma.

Methods

In this retrospective case series, we retrieved the clinical data of 21 eyes from 19 patients with open-angle uveitic glaucoma who were treated with ripasudil at Kobe University Hospital. We analyzed the median intraocular pressure (IOP) reductions after ripasudil treatment and collected the information on the adverse events that were encountered during the course of this treatment period.

Results

The causes of uveitis were sarcoidosis (29%), Behçet’s disease (14%), Vogt–Koyanagi–Harada disease (10%), others (15%), and unclassified (33%). Of total, 19 (90%) eyes were treated with topical, periocular, and/or systemic steroid therapies. The median number of glaucoma medications used before ripasudil treatment was 2, and the median follow-up time was 13 months. The median IOPs were 23 mmHg at baseline, 16 mmHg at 1 month, and 18 mmHg at 12 months with significant IOP reductions of − 3 mmHg at 1 month and − 2 mmHg at 12 months (P = 0.0050). Of total, 11 (52%) eyes with an IOP reduction ≥ 3 mmHg at 1 month (responders) showed a significant median IOP decrease at 12 months compared with non-responders (− 5 versus 0 mmHg, P = 0.0242). Two adverse events were observed: rashes on the back and transient conjunctival hyperemia.

Conclusions

Ripasudil appears to be safe and substantially reduce IOP in eyes with uveitic glaucoma if the eye is a responder. Ripasudil could be an option for the treatment of uveitic glaucoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Panek WC, Holland GN, Lee DA, Christensen RE (1990) Glaucoma in patients with uveitis. Br J Ophthalmol 74(4):223–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Herbert HM, Viswanathan A, Jackson H, Lightman SL (2004) Risk factors for elevated intraocular pressure in uveitis. J Glaucoma 13(2):96–99

    Article  PubMed  Google Scholar 

  3. Heinz C, Koch JM, Zurek-Imhoff B, Heiligenhaus A (2009) Prevalence of uveitic secondary glaucoma and success of nonsurgical treatment in adults and children in a tertiary referral center. Ocul Immunol Inflamm 17(4):243–248. https://doi.org/10.1080/09273940902913035

    Article  PubMed  Google Scholar 

  4. Kanda T, Shibata M, Taguchi M, Ishikawa S, Harimoto K, Takeuchi M (2014) Prevalence and aetiology of ocular hypertension in acute and chronic uveitis. Br J Ophthalmol 98(7):932–936. https://doi.org/10.1136/bjophthalmol-2013-304416

    Article  PubMed  Google Scholar 

  5. Siddique SS, Suelves AM, Baheti U, Foster CS (2013) Glaucoma and uveitis. Surv Ophthalmol 58(1):1–10. https://doi.org/10.1016/j.survophthal.2012.04.006

    Article  PubMed  Google Scholar 

  6. Hamanaka T, Takei A, Takemura T, Oritsu M (2002) Pathological study of cases with secondary open-angle glaucoma due to sarcoidosis. Am J Ophthalmol 134(1):17–26

    Article  PubMed  Google Scholar 

  7. Tektas OY, Heinz C, Heiligenhaus A, Hammer CM, Luetjen-Drecoll E (2011) Morphological changes of trabeculectomy specimens in different kinds of uveitic glaucoma. Curr Eye Res 36(5):442–448. https://doi.org/10.3109/02713683.2011.566409

    Article  PubMed  Google Scholar 

  8. Lu Z, Zhang Y, Freddo TF, Gong H (2011) Similar hydrodynamic and morphological changes in the aqueous humor outflow pathway after washout and Y27632 treatment in monkey eyes. Exp Eye Res 93(4):397–404. https://doi.org/10.1016/j.exer.2011.05.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kameda T, Inoue T, Inatani M, Fujimoto T, Honjo M, Kasaoka N, Inoue-Mochita M, Yoshimura N, Tanihara H (2012) The effect of Rho-associated protein kinase inhibitor on monkey Schlemm’s canal endothelial cells. Invest Ophthalmol Vis Sci 53(6):3092–3103. https://doi.org/10.1167/iovs.11-8018

    Article  CAS  PubMed  Google Scholar 

  10. Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, Tanihara H (2016) Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells. Sci Rep 6:19640. https://doi.org/10.1038/srep19640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, Suganami H, Araie M, Group KCS (2016) One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol 94(1):e26–e34. https://doi.org/10.1111/aos.12829

    Article  CAS  PubMed  Google Scholar 

  12. Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, Yamane S, Kadonosono K (2017) One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-017-3727-5

  13. Nussenblatt RB, Palestine AG, Chan CC (1985) Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1(4):369–382

    Article  CAS  PubMed  Google Scholar 

  14. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516

    Article  PubMed  Google Scholar 

  15. Markomichelakis NN, Kostakou A, Halkiadakis I, Chalkidou S, Papakonstantinou D, Georgopoulos G (2009) Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 247(6):775–780. https://doi.org/10.1007/s00417-009-1036-3

    Article  CAS  PubMed  Google Scholar 

  16. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389(6654):990–994. https://doi.org/10.1038/40187

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

    Sentaro Kusuhara, Atsuko Katsuyama, Wataru Matsumiya & Makoto Nakamura

Authors
  1. Sentaro Kusuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsuko Katsuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wataru Matsumiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makoto Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sentaro Kusuhara.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board (Kobe University Graduate School of Medicine) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Subjects’ informed consent was not required since this was a retrospective review.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kusuhara, S., Katsuyama, A., Matsumiya, W. et al. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 256, 809–814 (2018). https://doi.org/10.1007/s00417-018-3933-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-018-3933-9

Keywords

Search

Navigation